Australian biotech stocks slide as investor interest dries up
Excluding the Big Four, the next 40 largest Australian biotechs lost almost 10% of their value in October.
Thirty of the 40 smaller biotechs fell in value last month, with 24 dropping more than 10%. The broader Australian market gained about 1% over the same period.
In the US, the Nasdaq Biotechnology Index rose 3%. Among individual Australian players, EBR Systems fell 53%, Starpharma dropped 48%, and Botanix Pharmaceuticals, Saluda Medical and Lumos Diagnostics also declined sharply.
Avita Medical surged 45% despite no announcements, while Optiscan rose 15% and Nova Eye gained 13%. Clever Culture raised $2.6 million to develop a new benchtop automation system for smaller drug facilities.
- Almost 10% in October
- Biotech 40 loss
- 30 of 40, with 24 down over 10%
- Companies that fell
- EBR Systems (heart device) down 53%
- Biggest faller
- $2.6 million for benchtop automation
- Clever Culture fundraise
Why it mattersSmaller biotechs struggling to attract investors can starve innovation pipelines, even when companies have positive developments.
AustraliaAustralian biotech investors are punishing smaller companies despite real progress, creating pressure on local innovation and job growth in the sector.
